Idorsia/J&J’s Aprocitentan Hits Phase III Mark, Could Become First ET-1 Antagonist For Hypertension
The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.
You may also be interested in...
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
The firms’ gene therapy Hemgenix has won a US thumbs up for the treatment of hemophilia B and plans are underway for a US launch with a big price tag that experts agree should pay off in the long-term.
The Swiss firm has divested yet another one of its key programs in a bid to stave off insolvency and remain a listed company, forcing it to focus solely on a pre-IVF drug candidate.